MCID: INT075
MIFTS: 53

Intracranial Hypertension

Categories: Neuronal diseases

Aliases & Classifications for Intracranial Hypertension

MalaCards integrated aliases for Intracranial Hypertension:

Name: Intracranial Hypertension 12 53 54 43 15 17 71
Raised Intracranial Pressure 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9428
MeSH 43 D019586
NCIt 49 C84791
SNOMED-CT 67 28073009
UMLS 71 C0151740

Summaries for Intracranial Hypertension

NINDS : 53 Pseudotumor cerebri literally means "false brain tumor." It is likely due to high pressure within the skull caused by the buildup or poor absorption of cerebrospinal fluid (CSF). The disorder is most common in women between the ages of 20 and 50. Symptoms of pseudotumor cerebri, which include headache, nausea, vomiting, and pulsating sounds within the head, closely mimic symptoms of large brain tumors.

MalaCards based summary : Intracranial Hypertension, also known as raised intracranial pressure, is related to intracranial hypertension, idiopathic and papilledema, and has symptoms including vomiting, headache and papilledema. An important gene associated with Intracranial Hypertension is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Acetazolamide and Cisatracurium have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and pituitary, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 A brain disease that is characterized by high pressure inside the skull, the brain tissue and cerebrospinal fluid, has symptom headache, has symptom vomiting, has symptom altered mental status, has symptom papilledema.

Related Diseases for Intracranial Hypertension

Diseases related to Intracranial Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 783)
# Related Disease Score Top Affiliating Genes
1 intracranial hypertension, idiopathic 34.6 SSTR1 SLC12A3 F3 F2 AQP4 AQP1
2 papilledema 32.2 SERPINC1 F3 F2 APOH
3 hydrocephalus 31.5 TWIST1 TNF PRL MTHFR AQP4
4 brain edema 31.3 IL1B AQP4 AQP1
5 abducens nerve disease 31.1 SERPINC1 PRL AQP4
6 obstructive hydrocephalus 31.0 PRL AQP4 AQP1
7 sagittal sinus thrombosis 31.0 SERPINC1 F5 F3 F2
8 mastoiditis 31.0 SERPINC1 MTHFR F2
9 thrombophilia due to thrombin defect 31.0 SERPINE1 SERPINC1 MTHFR F5 F3 F2
10 lateral sinus thrombosis 30.9 SERPINC1 MTHFR F2
11 sleep apnea 30.9 TNF RETN IL1B ADIPOQ
12 encephalitis 30.8 TNF IL1B CXCL10 AQP4
13 pulmonary edema 30.8 TNF SERPINC1 IL1B F2
14 hepatic encephalopathy 30.8 TNF F2 AQP4
15 bacterial meningitis 30.7 TNF IL1B AQP4
16 thrombocytosis 30.7 SERPINC1 IL1B F3 F2
17 compartment syndrome 30.7 TNF SERPINC1 F3 F2
18 severe pre-eclampsia 30.6 SERPINC1 F5 APOH ADIPOQ
19 migraine with or without aura 1 30.6 TNF PRL MTHFR IL1B F2 CACNA1A
20 thrombosis 30.5 SERPINE1 SERPINC1 MTHFR F9 F5 F3
21 leptin deficiency or dysfunction 30.5 TNF RETN ADIPOQ
22 intracranial sinus thrombosis 30.4 SERPINC1 MTHFR F3 F2
23 nonarteritic anterior ischemic optic neuropathy 30.4 SERPINC1 MTHFR F5 F2
24 myelitis 30.4 TNF MTHFR AQP4 APOH
25 meningococcemia 30.4 SERPINE1 SERPINC1 IL1B F5
26 neuritis 30.4 TNF IL1B CXCL10 AQP4
27 transverse myelitis 30.4 TNF AQP4 APOH
28 viral encephalitis 30.4 TNF IL1B CXCL10
29 adult respiratory distress syndrome 30.3 TNF SERPINE1 IL1B F2
30 toxic shock syndrome 30.3 TNF SERPINC1 IL1B F3
31 transient cerebral ischemia 30.3 MTHFR IL1B APOH
32 purpura 30.3 TNF SERPINC1 F3 F2 APOH
33 exanthem 30.3 TNF F3 F2
34 retinal vascular disease 30.3 TNF MTHFR IL1B
35 respiratory failure 30.3 TNF IL1B F3 F2 CXCL10
36 cerebral artery occlusion 30.3 TNF IL1B AQP4
37 optic neuritis 30.3 TNF IL1B CXCL10 AQP4
38 eclampsia 30.2 TNF SERPINE1 SERPINC1 MTHFR F2
39 thrombophilia 30.2 SERPINE1 SERPINC1 MTHFR F9 F5 F3
40 migraine without aura 30.2 TNF PRL MTHFR
41 typhoid fever 30.2 TNF IL1B F2
42 demyelinating disease 30.2 TNF IL1B CXCL10 AQP4
43 neuromyelitis optica 30.2 CXCL10 AQP4 AQP1
44 factor viii deficiency 30.2 F9 F5 F3 F2
45 leptospirosis 30.1 TNF IL1B F2 AQP1
46 intracranial thrombosis 30.1 SERPINC1 MTHFR F5 F3 F2 APOH
47 apnea, obstructive sleep 30.1 TNF SERPINE1 RETN ADIPOQ
48 acute promyelocytic leukemia 30.1 TNF SERPINE1 SERPINC1 IL1B F3 F2
49 sickle cell anemia 30.1 TNF MTHFR F2
50 cerebral sinovenous thrombosis 30.1 MTHFR F5 F3 F2 APOH

Graphical network of the top 20 diseases related to Intracranial Hypertension:



Diseases related to Intracranial Hypertension

Symptoms & Phenotypes for Intracranial Hypertension

Symptoms:

12
  • vomiting
  • headache
  • papilledema
  • altered mental status

UMLS symptoms related to Intracranial Hypertension:


bulging fontanelle

MGI Mouse Phenotypes related to Intracranial Hypertension:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 ADIPOQ APOH AQP1 AQP4 CACNA1A CXCL10
2 cardiovascular system MP:0005385 10.32 ADIPOQ AQP1 AQP4 CXCL10 F2 F3
3 growth/size/body region MP:0005378 10.23 ADIPOQ AQP1 AQP4 CACNA1A F2 F3
4 hematopoietic system MP:0005397 10.21 ADIPOQ AQP1 AQP4 CACNA1A CXCL10 F2
5 immune system MP:0005387 10.18 ADIPOQ AQP4 CACNA1A CXCL10 F2 F3
6 mortality/aging MP:0010768 10.06 ADIPOQ APOH AQP1 AQP4 CACNA1A CXCL10
7 integument MP:0010771 10.02 ADIPOQ CACNA1A F2 F3 F5 IL1B
8 liver/biliary system MP:0005370 9.91 ADIPOQ F5 F9 MTHFR PRL RETN
9 nervous system MP:0003631 9.83 ADIPOQ AQP1 AQP4 CACNA1A CXCL10 F2
10 respiratory system MP:0005388 9.23 ADIPOQ AQP1 AQP4 CACNA1A F2 F3

Drugs & Therapeutics for Intracranial Hypertension

Drugs for Intracranial Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
2
Cisatracurium Approved Phase 4 96946-41-7
3
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
4
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
5
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
6
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
7
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
8
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
9
Remifentanil Approved Phase 4 132875-61-7 60815
10
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
11
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
12
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
13
Racepinephrine Approved Phase 4 329-65-7 838
14
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
15 Natriuretic Agents Phase 4
16 diuretics Phase 4
17 Carbonic Anhydrase Inhibitors Phase 4
18 Neuromuscular Agents Phase 4
19 Neuromuscular Blocking Agents Phase 4
20 Neuromuscular Nondepolarizing Agents Phase 4
21 Cholinergic Antagonists Phase 4
22 Cholinergic Agents Phase 4
23 Anticonvulsants Phase 4
24 Central Nervous System Depressants Phase 4
25 Narcotics Phase 4
26 Analgesics, Opioid Phase 4
27 Analgesics Phase 4
28 Anti-Arrhythmia Agents Phase 4
29 calcium channel blockers Phase 4
30 Calcium, Dietary Phase 4
31 Anesthetics, Local Phase 4
32 Tocolytic Agents Phase 4
33 Sodium Channel Blockers Phase 4
34 Diuretics, Potassium Sparing Phase 4
35 Epinephryl borate Phase 4
36
Esmolol Approved Phase 3 81147-92-4, 103598-03-4 59768
37
Quinine Approved Phase 2, Phase 3 130-95-0 8549 3034034
38
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
39
Amphetamine Approved, Illicit, Investigational Phase 3 300-62-9 5826 3007
40
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
41
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
42
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516
43
Naproxen Approved, Vet_approved Phase 2, Phase 3 22204-53-1 1302 156391
44
Codeine Approved, Illicit Phase 2, Phase 3 76-57-3 5284371
45
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
46
Dexmedetomidine Approved, Vet_approved Phase 3 113775-47-6 68602 5311068
47
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
48
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
49
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029
50
Rifampicin Approved Phase 3 13292-46-1 5458213 5381226

Interventional clinical trials:

(show top 50) (show all 214)
# Name Status NCT ID Phase Drugs
1 Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents. A Controlled Randomized Study Versus Placebo Unknown status NCT02404779 Phase 4 cisatracurium besilate
2 Prospective Open-label Phase IV Trial to Investigate the Frequency of Optic Disc Swelling, Idiopathic Intracranial Hypertension and Dry Eye Symptoms Under Antiacne Medication Treatment Unknown status NCT02149615 Phase 4
3 Comparison of the Efficacy Between 20% Mannitol and 3% Hypertonic Saline, Given as a Bolus at the Beginning of Elective Supratentorial Craniotomy for Tumor Resection, in Favoring Cerebral Relaxation Evaluated by a Sub-dural Intracranial Pressure Measurement. Unknown status NCT01745081 Phase 4 20% mannitol bolus administration;Hypertonic saline 3% bolus administration
4 Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery Unknown status NCT02964416 Phase 4 Injection Tramadol
5 A Randomised Controlled Trial of the Effectiveness of Acetazolamide in Reducing Cerebrospinal Fluid Pressure for Patients Undergoing Thoracic-abdominal Aortic Repair Unknown status NCT01889498 Phase 4 Acetazolamide
6 Equimolar Doses of Mannitol and Hypertonic Saline in the Treatment of Elevated Intracranial Pressure Completed NCT00447018 Phase 4 20% mannitol;7.45% hypertonic saline solution
7 Correlation of Measured and Calculated Serum Osmolality During Mannitol or Hypertonic Saline Infusion in Patients After Craniotomy Completed NCT02037815 Phase 4 20% mannitol solution, 125 ml, IV infusion in 15 min;3.1% sodium chloride solution, 125 ml, IV infusion in 15 min
8 Effect of Intravenous Infusion of Lidocaine, Magnesium Sulphate and Remifentanil Perioperatively in Patients Undergoing Mastectomy: a Prospective, Randomized and Double-blind Study Completed NCT02309879 Phase 4 Remifentanil infusion;Lidocaine infusion;Magnesium sulphate infusion;Magnesium sulphate and Lidocaine infusion
9 Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies Recruiting NCT02951559 Phase 4
10 Compared Effects of 2 Doses of Mannitol on Post Traumatic Intracranial Hypertension Terminated NCT00795587 Phase 4 variation of mannitol dose
11 Accuracy of ShuntCheck and MRI in Detection of Shunt Obstruction in Patients Receiving Shunt Patency Test Withdrawn NCT00793416 Phase 4
12 Effect of Mannitol as Adjunct Therapy on the Clinical Outcome of Childhood Cerebral Malaria in Mulago Hospital: A Randomised Clinical Trial Unknown status NCT00113854 Phase 3 Mannitol
13 Scientific Research and Development of Innovative Evidence Based Non-invasive Brain Diagnostic and Monitoring Solutions for Neurological and Traumatic Brain Injury Patients Unknown status NCT02130219 Phase 2, Phase 3
14 Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures Unknown status NCT02563288 Phase 3 Esmolol;Dexmedetomidine
15 Randomized Trial of Erythropoietin to Prevent Death From Cerebral Impairment During Severe Malaria Unknown status NCT00697164 Phase 2, Phase 3 Placebo;Erythropoietin
16 Multi-centre Prospective Randomised Trial of Early Decompressive Craniectomy in Patients With Severe Traumatic Brain Injury Unknown status NCT00155987 Phase 3
17 An Open-label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence (COATS) Unknown status NCT02541500 Phase 3 Minocycline
18 A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss Completed NCT01003639 Phase 2, Phase 3 Acetazolamide;Placebo
19 Randomized Double-Blind Placebo-Controlled Trial of Oral Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness. Completed NCT00664001 Phase 3
20 Effect of Preventive Sodium Lactate Infusion on Intracranial Hypertension in Severe Trauma Tic Brain Injury Completed NCT00995683 Phase 2, Phase 3 half molar sodium lactate;isotonic sodium chloride
21 Cerebral Perfusion Pressure Using Precedex and Other Sedatives Completed NCT01169467 Phase 3 Standard-of-Care plus Dexmedetomidine
22 Anesthesiological Strategies in Elective Craniotomy: Randomized, Equivalence, Open Trial Completed NCT00741351 Phase 3 Sevoflurane + Fentanyl;Sevoflurane + Remifentanyl;Propofol + Remifentanyl
23 The Impact of Ventricular Catheter Impregnated With Antimicrobial Agents on Infection in Patients With Ventricular Catheter: A Prospective Randomized Study Completed NCT00286104 Phase 3
24 Pilot Study of Early and Prolonged Hypothermia in Severe Traumatic Brain Injury in Children Completed NCT00282269 Phase 2, Phase 3
25 Double Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Repetitive Transcranial Magnetic Stimulation in Patients Victims of Landmines With Phantom Limb Pain Completed NCT01872481 Phase 3
26 Continuous Hyperosomolar Therapy for Traumatic Brain-injured Patients Study Protocol for a Multicenter Randomized Open-label Trial With Blinded Adjudication of Primary Outcome Recruiting NCT03143751 Phase 3 NaCl20% (Continuous hyperosmolar therapy)
27 Transfusion Strategies in Acute Brain Injured Patients. A Prospective Multicenter Randomized Study. Recruiting NCT02968654 Phase 3
28 Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss Active, not recruiting NCT03501966 Phase 3 Acetazolamide
29 Effect of Molar Sodium Lactate Filling on Cerebral Hemodynamics in Patients With Severe Meningeal Hemorrhage Multicenter Randomized Study Not yet recruiting NCT04141371 Phase 3 Molar Sodium Lactate;physiological serum
30 Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension. Terminated NCT00622570 Phase 3 Pentobarbital;thiopental
31 Normal Pressure Hydrocephalus Treatment by Acetazolamide Terminated NCT02163330 Phase 3 Acetazolamide;sugar pill
32 Mannitol Versus Hypertonic Saline to Treat Intracranial Hypertension After Severe Traumatic Brain Injury : a Comparative Study on the Effects on PtiO2 and Microdialysis Values Terminated NCT01028339 Phase 3 Hypertonic saline;Mannitol
33 Sodium-Lactate Versus Mannitol in the Treatment of Intracranial Hypertensive Episodes in Severe Traumatic Brain Injured Patients Terminated NCT00319345 Phase 2, Phase 3 Mannitol, Sodium-Lactate
34 Pediatric Traumatic Brain Injury Consortium: Hypothermia Terminated NCT00222742 Phase 3
35 Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure Terminated NCT01111682 Phase 3 Mannitol;Hypertonic Saline
36 Phase II/III, Randomized, Clinical Trial of the Effects of Nutropin AQ® on Growth and Bone Metabolism in Children With MPS I, II, and VI and Short Stature Terminated NCT00748969 Phase 2, Phase 3 Somatropin (DNA origin)
37 Treatment of Suspected Cholelithiasis With Nitroglycerin: a Randomized, Prospective Double-blind Trial Unknown status NCT01715220 Phase 2 sublingual nitroglycerine
38 Intraventricular Tissue Plasminogen Activator in the Management of Aneurysmal Subarachnoid Hemorrhage: a Randomized Controlled Pilot Study Unknown status NCT01098890 Phase 2 Tissue Plasminogen Activator;Placebo
39 Feasibility of Dexmedetomidine-based Sedation in Neurocritical Care Patients : a Pilot Study Unknown status NCT02252523 Phase 2 Dexmedetomidine
40 Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study. Completed NCT02017444 Phase 2 AZD4017
41 Dexamethasone in Cryptococcal Meningitis Completed NCT00000776 Phase 2 Flucytosine;Fluconazole;Amphotericin B;Dexamethasone
42 7.2% NaCl in 6% Hydroxyethyl Starch Versus Placebo - Effect on Intracranial Pressure and Haemodynamics in Subarachnoidal Haemorrhage (SAH) Patients. Completed NCT00199706 Phase 2 7.2% NaCl in 6% hydroxyethyl starch solution
43 A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal Completed NCT01856205 Phase 2 Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
44 Intranasal Ketamine for Treatment of Acute Pain in the Emergency Department : A Randomized Controlled Trial Completed NCT03233035 Phase 2 Ketamine;Placebo
45 Phase 2, Randomized Clinical Trial of the Safety and Efficacy of Brain Tissue Oxygen Monitoring in the Management of Severe Traumatic Brain Injury. Completed NCT00974259 Phase 2
46 Phase 1/Phase 2, Single-Center, Controlled Study of the Effectiveness of Combined High Frequency Oscillation and Tracheal Gas Insufflation in Improving the Clinical Course of Patients With Severe Acute Respiratory Distress Syndrome Completed NCT00416260 Phase 1, Phase 2
47 The Effect of Single-dose Propofol Injection on Pain and Quality of Life in Chronic Daily Headache: a Randomized Double-blind Controlled Trial Completed NCT00228267 Phase 2 Propofol
48 Acetazolamide for Treating NPH in Shunt-candidates Patients: an Open Label Feasibility Trial Recruiting NCT03779594 Phase 2 Acetazolamide
49 Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial) Recruiting NCT03354143 Phase 2 Standard Care;Intensive Treatment
50 A Proof-of-concept Study to Assess the Effect of Recombinant Human Growth Hormone on the Size of the Replication-competent Viral Reservoir in HIV-infected Individuals on Suppressive Antiretroviral Therapy Recruiting NCT03091374 Phase 2 Somatotropin (Human)

Search NIH Clinical Center for Intracranial Hypertension

Inferred drug relations via UMLS 71 / NDF-RT 50 :


carbamide peroxide
Thiopental
Thiopental Sodium
Urea
UREA POWDER

Cochrane evidence based reviews: intracranial hypertension

Genetic Tests for Intracranial Hypertension

Anatomical Context for Intracranial Hypertension

MalaCards organs/tissues related to Intracranial Hypertension:

40
Brain, Liver, Pituitary, Bone, Testes, Spinal Cord, Pineal

Publications for Intracranial Hypertension

Articles related to Intracranial Hypertension:

(show top 50) (show all 9238)
# Title Authors PMID Year
1
Anterior ischemic optic neuropathy in a patient with papilledema from idiopathic intracranial hypertension. 61
31956730 2020
2
Point-of-care handheld ophthalmic ultrasound in the diagnosis and evaluation of raised intracranial pressure and Terson syndrome: a description of two cases. 61
31758491 2020
3
Hyperosmolar therapy for acute brain injury: study protocol for an umbrella review of meta-analyses and an evidence mapping. 61
32034026 2020
4
Cerebrospinal fluid dynamics modulation by diet and cytokines in rats. 61
32036786 2020
5
Hypertonic Saline is Superior to Mannitol for the Combined Effect on Intracranial Pressure and Cerebral Perfusion Pressure Burdens in Patients With Severe Traumatic Brain Injury. 61
30877299 2020
6
Fluid Overload in Pediatric Severe Traumatic Brain Injury. 61
31568241 2020
7
Patient outcomes at twelve months after early decompressive craniectomy for diffuse traumatic brain injury in the Randomized DECRA Clinical Trial. 61
32027212 2020
8
Assessment of intracranial pressure monitoring in patients with moderate traumatic brain injury: A retrospective cohort study. 61
31846845 2020
9
A Consensus-Based Management Protocol For The Treatment Of Severe Traumatic Brain Injury Based On Imaging And Clinical Examination For Use When Intracranial Pressure Monitoring Is Not Employed. 61
32013721 2020
10
Long-Term Effect of Decompressive Craniectomy on Intracranial Pressure and Possible Implications for Intracranial Fluid Movements. 61
30768137 2020
11
CRyptOcoccosis in Newcastle and the hUnTer (CRONUT) - An epidemiological study. 61
31501070 2020
12
Optic nerve sheath diameter in children with acute liver failure: A prospective observational pilot study. 61
31549476 2020
13
Intracranial pressure, brain morphology and cognitive outcome in children with sagittal craniosynostosis. 61
32016575 2020
14
Forecasting intracranial hypertension using multi-scale waveform metrics. 61
31851948 2020
15
Dynamic nature of intracranial venous sinuses in idiopathic intracranial hypertension. 61
31438747 2020
16
Optic nerve sheath diameter asymmetry in healthy subjects and patients with intracranial hypertension. 61
31586289 2020
17
Lumboperitoneal and Ventriculoperitoneal Shunting for Idiopathic Intracranial Hypertension Demonstrate Comparable Failure and Complication Rates. 61
30937428 2020
18
Idiopathic intracranial hypertension is not idiopathic: proposal for a new nomenclature and patient classification. 61
31776170 2020
19
Intracranial hypertension in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. 61
32008128 2020
20
Western Trauma Association critical decisions in trauma: Management of intracranial hypertension in patients with severe traumatic brain injuries. 61
31999657 2020
21
"Lumboperitoneal shunt as a resolution for idiopathic intracranial hypertension. What to expect while pregnant, a case report". 61
31902543 2020
22
The Cushing reflex and the vasopressin-mediated hemodynamic response to increased intracranial pressure during acute elevations in intraabdominal pressure. 61
31813477 2020
23
Surgical management of raised intracranial pressure secondary to otogenic infection and venous sinus thrombosis. 61
31444559 2020
24
Ocular sonography in pre-eclampsia: a simple technique to detect raised intracranial pressure? 61
31704252 2020
25
Optic Nerve Tortuosity on Earth and in Space. 61
31980047 2020
26
Neuroimaging findings in patients with idiopathic intracranial hypertension and cerebral venous thrombosis, and their association with clinical features. 61
31910744 2020
27
Circadian disruption of core body temperature in trauma patients: a single-center retrospective observational study. 61
31921428 2020
28
Optic nerve sheath diameter measurement for predicting raised intracranial pressure in adult patients with severe traumatic brain injury: A meta-analysis. 61
31945584 2020
29
Venous Sinus Stenting for Transverse Sinus Stenosis Associated with Leptomeningeal Carcinomatosis in a Patient with Epidermal Growth Factor Receptor-Mutated Lung Cancer: A Case Report. 61
31929495 2020
30
Assessment of Skin Flaps Above Cranial Defects Following Craniectomy: A Proposed Classification System. 61
31590193 2020
31
Ultrasound non-invasive intracranial pressure assessment in paediatric neurocritical care: a pilot study. 61
31203395 2020
32
A management algorithm for adult patients with both brain oxygen and intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). 61
31965267 2020
33
Early Osmotherapy in Severe Traumatic Brain Injury: An International Multicenter Study. 61
31286839 2020
34
MRI Findings in Acute Hyperammonemic Encephalopathy: Three Cases of Different Etiologies: Teaching Point: To recognize MRI findings in acute hyperammonemic encephalopathy. 61
32025625 2020
35
Decompressive Craniectomy: A Preliminary Study of Comparative Radiographic Characteristics Predicting Outcome in Malignant Ischemic Stroke. 61
31505293 2020
36
Custom shunt system for increased baseline intracranial pressure in a patient with idiopathic intracranial hypertension. 61
31996337 2020
37
Predictors of intracranial hypertension in children undergoing ICP monitoring after severe traumatic brain injury. 61
31970473 2020
38
EVENTS ASSOCIATED WITH THE OCCURRENCE OF INTRACRANIAL HYPERTENSION IN PEDIATRIC PATIENTS WITH SEVERE CRANIOENCEPHALIC TRAUMA AND MONITORING OF INTRACRANIAL PRESSURE. 61
31939519 2020
39
Idiopathic intracranial hypertension: shunt failure and the role of obesity. 61
31954904 2020
40
Urgent Chemotherapy Successfully Rescues a Near Death Patient of Acute Intracranial Hypertension Caused by Intracranial Myeloid Sarcoma. 61
32021270 2020
41
Guide to preclinical models used to study the pathophysiology of idiopathic intracranial hypertension. 61
31896803 2020
42
Successful resolution of the ophthalmic manifestations of a falcotentorial meningioma through Cerebrospinal fluid diversion. 61
31843434 2020
43
Mild Hyperventilation in Traumatic Brain Injury-Relation to Cerebral Energy Metabolism, Pressure Autoregulation, and Clinical Outcome. 61
31561041 2020
44
Predictors of Surgical Site Infection in Autologous Cranioplasty: A Retrospective Analysis of Subcutaneously Preserved Bone Flaps in Abdominal Pockets. 61
31568916 2020
45
Effect of half-molar sodium lactate infusion on biochemical parameters in critically ill patients. 61
31973954 2020
46
Neoplastic meningitis in solid tumours: Updated review of diagnosis, prognosis, therapeutic management, and future directions. 61
31964538 2020
47
Endovascular treatment of cerebral venous sinus stenosis based on hemodynamic assessment using pressure wire: case report. 61
32001411 2020
48
How to use cerebral ultrasound in the ICU. 61
31922373 2020
49
Dynamic optic nerve sheath diameter changes upon moderate hyperventilation in patients with traumatic brain injury. 61
31982696 2020
50
Decompressive craniectomy with scalp expansion graft using a temporary synthetic skin substitute in the pediatric population: case series and review of the literature. 61
31965291 2020

Variations for Intracranial Hypertension

Expression for Intracranial Hypertension

Search GEO for disease gene expression data for Intracranial Hypertension.

Pathways for Intracranial Hypertension

Pathways related to Intracranial Hypertension according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.13 SERPINE1 SERPINC1 F9 F5 F3 F2
2
Show member pathways
12.67 SERPINC1 F9 F5 F3 F2
3
Show member pathways
12.05 TNF SERPINE1 MTHFR IL1B F2
4
Show member pathways
12.04 TNF SERPINE1 IL1B F3
5 11.97 TNF SSTR1 IL1B AQP4
6 11.78 TWIST1 TNF SERPINE1 RETN ADIPOQ
7 11.71 TNF SERPINE1 IL1B F3
8 11.63 TNF IL1B CXCL10 AQP4 AQP1
9
Show member pathways
11.63 SERPINE1 SERPINC1 F9 F5 F3 F2
10 11.56 TNF IL1B CXCL10
11 11.34 TNF IL1B CXCL10
12 11.26 SERPINE1 SERPINC1 F9 F5 F3 F2
13 11.1 TNF MTHFR IL1B
14 10.89 TWIST1 TNF ADIPOQ
15 10.48 TNF PRL

GO Terms for Intracranial Hypertension

Cellular components related to Intracranial Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TNF SERPINE1 SERPINC1 RETN PRL IL1B
2 collagen-containing extracellular matrix GO:0062023 9.7 SERPINE1 SERPINC1 F9 F3 F2 APOH
3 extracellular space GO:0005615 9.44 TNF SERPINE1 SERPINC1 RETN PRL IL1B

Biological processes related to Intracranial Hypertension according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.92 TWIST1 TNF IL1B F3 CXCL10
2 cellular protein metabolic process GO:0044267 9.91 SERPINC1 PRL F5 F2
3 positive regulation of protein phosphorylation GO:0001934 9.88 TNF IL1B F2 ADIPOQ
4 cellular response to lipopolysaccharide GO:0071222 9.87 TNF SERPINE1 IL1B CXCL10
5 blood coagulation GO:0007596 9.85 SERPINC1 F9 F5 F3 F2
6 positive regulation of inflammatory response GO:0050729 9.8 TNF SERPINE1 IL1B
7 regulation of insulin secretion GO:0050796 9.77 TNF IL1B CACNA1A
8 negative regulation of endothelial cell proliferation GO:0001937 9.71 TNF PRL APOH
9 positive regulation of interleukin-6 secretion GO:2000778 9.69 TWIST1 TNF IL1B
10 positive regulation of JAK-STAT cascade GO:0046427 9.65 TNF PRL F2
11 positive regulation of angiogenesis GO:0045766 9.65 TWIST1 SERPINE1 IL1B F3 AQP1
12 positive regulation of neuroinflammatory response GO:0150078 9.62 TNF IL1B
13 positive regulation of chemokine biosynthetic process GO:0045080 9.62 TNF IL1B
14 multicellular organismal water homeostasis GO:0050891 9.61 AQP4 AQP1
15 blood coagulation, intrinsic pathway GO:0007597 9.61 F9 F2 APOH
16 negative regulation of synaptic transmission GO:0050805 9.6 IL1B ADIPOQ
17 regulation of establishment of endothelial barrier GO:1903140 9.58 TNF IL1B
18 positive regulation of blood coagulation GO:0030194 9.58 SERPINE1 F2 APOH
19 positive regulation of fever generation GO:0031622 9.56 TNF IL1B
20 sequestering of triglyceride GO:0030730 9.55 TNF IL1B
21 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.54 TWIST1 IL1B ADIPOQ
22 regulation of blood coagulation GO:0030193 9.5 SERPINC1 F2 APOH
23 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 TNF IL1B
24 negative regulation of fibrinolysis GO:0051918 9.33 SERPINE1 F2 APOH
25 positive regulation of interleukin-8 production GO:0032757 9.26 TNF SERPINE1 IL1B ADIPOQ
26 hemostasis GO:0007599 9.02 SERPINC1 F9 F5 F3 F2

Molecular functions related to Intracranial Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 TNF IL1B CXCL10 ADIPOQ
2 water channel activity GO:0015250 9.26 AQP4 AQP1
3 heparin binding GO:0008201 9.26 SERPINC1 F2 CXCL10 APOH
4 protease binding GO:0002020 8.92 TNF SERPINE1 SERPINC1 F3

Sources for Intracranial Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....